A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer

P. Pronzato, G. Bertelli, A. Vigani, F. Vaira

Research output: Contribution to journalArticle


We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%).

Original languageEnglish
Pages (from-to)1425-1427
Number of pages3
JournalBritish Journal of Cancer
Issue number11
Publication statusPublished - 1996



  • Dose intensity
  • Ovarian cancer
  • Polychemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this